A conversation with Prof. Przemysław Mitkowski, president of the Polish Society of Cardiology.
We have an increasing number of reports on guidelines for the use of flosins, not only in patients with diabetes and nephrology problems, but also in cardiac patients. How do you assess the importance of flosins therapy in your patients, especially those with heart failure, with preserved ejection fraction?
At the moment, we are no longer wondering why the patient has phlozin, rather why the patient did not get phlozin. This is indeed a drug that does not adversely affect ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
